SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Theodore Roosevelt Synthetic CCD

PatientTheodore Roosevelt
Date of birth2002-10-27
IdentifiersMRN HR-NI012-SYN; SSN (made up) 000-12-6157
Document date2026-11-01
AuthorAmos Kettering, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for frequent wheeze, night cough, and breathlessness during training. Concerns: Wheeze, night cough, and breathlessness are limiting his training and his long days at work; Would rather control his asthma with exercise than with daily medicine. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two inhalations as needed for wheeze (bought after an urgent care visit; used most days before intake)Two inhalations every 4 hours as neededRespiratory tract route2025-12-15 to 2026-03-09stoppedS
Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenanceTwo inhalations twice daily, with a spacer, rinsing the mouth afterwardsRespiratory tract route2026-03-09activeS
Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in totalOne inhalation as needed, repeated after a few minutes if needed; maximum 12 inhalations a day including maintenance dosesRespiratory tract route2026-03-09activeS
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning for 5 daysTwo tablets by mouth each morning for 5 daysOral route2026-08-03 to 2026-08-07completedS

Procedures

ProcedureDatesStatusEvidence
Spirometry before and after albuterol 400 mcg: FEV1 3.20 L (72 percent predicted), FEV1/FVC 0.67, FEV1 rising to 3.74 L after bronchodilator2026-03-09 to 2026-03-09completedS
Written asthma action plan with symptom and peak-flow zones; peak flow meter issued2026-03-09 to 2026-03-09completedS
Spirometry after three months of controller therapy: FEV1 3.98 L (89 percent predicted), FEV1/FVC 0.792026-06-08 to 2026-06-08completedS

Immunizations

DateVaccineStatusEvidence
2025-10-14Influenza vaccine, 2025-2026 seasoncompletedS
2019-08-12Tdap vaccinecompletedS
2014-04-07HPV 9-valent vaccine, two-dose series completedcompletedS
2026-04-06Pneumococcal conjugate vaccine PCV20completedS
2026-10-19Influenza vaccine, 2026-2027 seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1860sSevere childhood asthma, with night attacks in which he sat up in bed gasping, and trips away from home to find a place where he could breatheD (CLM-0002)
1872Near-sightedness discovered at about thirteen; first spectaclesD (CLM-0004)
1872Asthma attack at nearly fourteen, after which he was sent to Moosehead Lake and began boxing and a program of physical trainingD (CLM-0003)

Family History

RelativeConditionAge at deathEvidence
fatherDied in 1878, shortly after a diagnosis of stomach cancerD (CLM-0007)

Health Concerns

ConcernStatusEvidence
Wheeze, night cough, and breathlessness are limiting his training and his long days at workactiveS
Would rather control his asthma with exercise than with daily medicineactiveS

Assessment

Most recent measures: FEV1 --pre bronchodilation 3.2 on 2026-03-09; FEV1 measured/predicted 89 on 2026-06-08; Forced vital capacity [Volume] Respiratory system 5.02 on 2026-06-08; FEV1/FVC 0.79 on 2026-06-08; FEV1 --post bronchodilation 3.74 on 2026-03-09; Total score [ACT] 21 on 2026-09-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-19; Fractional concentration of exhaled nitric oxide 46 on 2026-04-06; Eosinophils [#/volume] in Blood by Automated count 0.42 on 2026-04-06; IgE [Units/volume] in Serum or Plasma 260 on 2026-04-06; European house dust mite IgE Ab [Units/volume] in Serum 8.4 on 2026-04-06; FEV1 3.98 on 2026-06-08; Maximum expiratory gas flow Respiratory system airway by Peak flow meter 420 on 2026-08-03; Total score [AUDIT-C] 1 on 2026-10-19 [S]

Strengths and supports: Supports: close friends, a boxing coach, and colleagues at work [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthmaactiveconfirmed J45.40S — Synthetic modern classification confirmed by spirometry; the historical asthma is D and its persistence into adulthood is R.
Myopia, both eyes, corrected with glasses since boyhoodactiveconfirmed H52.13S — Synthetic modern entry linked to his documented near-sightedness.
Moderate asthma exacerbation triggered by a viral cold, treated in the office with a five-day prednisone course; resolvedresolvedconfirmed J45.41S — Synthetic exacerbation at an unscheduled visit; viral infection is the most common trigger of asthma exacerbations. It does not echo a dated historical episode.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-09FEV1 --pre bronchodilation3.2L>=3.65 LLowS
2026-03-09FEV1 measured/predicted72%>=80%LowS
2026-03-09Forced vital capacity [Volume] Respiratory system4.8L>=4.4 LNormalS
2026-03-09FEV1/FVC0.67{ratio}>=0.72LowS
2026-03-09FEV1 --post bronchodilation3.74L>=3.65 LNormalS
2026-03-09Total score [ACT]13{score}S
2026-03-09Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-04-06Total score [ACT]18{score}S
2026-04-06Fractional concentration of exhaled nitric oxide46[ppb]<=25 [ppb]HighS
2026-04-06Eosinophils [#/volume] in Blood by Automated count0.4210*3/uL0-0.5 10*3/uLNormalS
2026-04-06IgE [Units/volume] in Serum or Plasma260[IU]/mL<=100 [IU]/mLHighS
2026-04-06European house dust mite IgE Ab [Units/volume] in Serum8.4k[IU]/L<=0.35 k[IU]/LHighS
2026-06-08FEV13.98L>=3.65 LNormalS
2026-06-08FEV1 measured/predicted89%>=80%NormalS
2026-06-08Forced vital capacity [Volume] Respiratory system5.02L>=4.4 LNormalS
2026-06-08FEV1/FVC0.79{ratio}>=0.72NormalS
2026-06-08Maximum expiratory gas flow Respiratory system airway by Peak flow meter605L/min80 percent or more of his personal best of 610 L/min (green zone)NormalS
2026-06-08Total score [ACT]22{score}S
2026-09-14Maximum expiratory gas flow Respiratory system airway by Peak flow meter590L/min80 percent or more of his personal best of 610 L/min (green zone)NormalS
2026-09-14Total score [ACT]21{score}S
2026-08-03Maximum expiratory gas flow Respiratory system airway by Peak flow meter420L/min80 percent or more of his personal best of 610 L/min (green zone)LowS
2026-10-19Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-19Total score [AUDIT-C]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-03-09Body height175cmS
2026-03-09Body weight72kgS
2026-03-09Body mass index (BMI) [Ratio]23.5kg/m2S
2026-03-09Systolic blood pressure118mm[Hg]S
2026-03-09Diastolic blood pressure72mm[Hg]S
2026-03-09Heart rate84/minS
2026-03-09Respiratory rate18/minS
2026-03-09Body temperature36.8CelS
2026-03-09Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-04-06Body height175cmS
2026-04-06Body weight72.4kgS
2026-04-06Body mass index (BMI) [Ratio]23.6kg/m2S
2026-04-06Systolic blood pressure116mm[Hg]S
2026-04-06Diastolic blood pressure70mm[Hg]S
2026-04-06Heart rate76/minS
2026-04-06Respiratory rate16/minS
2026-04-06Body temperature36.7CelS
2026-04-06Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-06-08Body height175cmS
2026-06-08Body weight73kgS
2026-06-08Body mass index (BMI) [Ratio]23.8kg/m2S
2026-06-08Systolic blood pressure118mm[Hg]S
2026-06-08Diastolic blood pressure74mm[Hg]S
2026-06-08Heart rate70/minS
2026-06-08Respiratory rate14/minS
2026-06-08Body temperature36.6CelS
2026-06-08Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-14Body height175cmS
2026-09-14Body weight73.2kgS
2026-09-14Body mass index (BMI) [Ratio]23.9kg/m2S
2026-09-14Systolic blood pressure116mm[Hg]S
2026-09-14Diastolic blood pressure72mm[Hg]S
2026-09-14Heart rate68/minS
2026-09-14Respiratory rate14/minS
2026-09-14Body temperature36.7CelS
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-03Body height175cmS
2026-08-03Body weight72.2kgS
2026-08-03Body mass index (BMI) [Ratio]23.6kg/m2S
2026-08-03Systolic blood pressure122mm[Hg]S
2026-08-03Diastolic blood pressure76mm[Hg]S
2026-08-03Heart rate98/minS
2026-08-03Respiratory rate20/minS
2026-08-03Body temperature37.6CelS
2026-08-03Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-10-19Body height175cmS
2026-10-19Body weight73.5kgS
2026-10-19Body mass index (BMI) [Ratio]24kg/m2S
2026-10-19Systolic blood pressure118mm[Hg]S
2026-10-19Diastolic blood pressure70mm[Hg]S
2026-10-19Heart rate66/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-03-09Primary care visit for frequent wheeze, night cough, and breathlessness during trainingfinishedS
2026-04-06Four-week asthma review after starting maintenance-and-reliever therapy, with pulmonology consultationfinishedS
2026-06-08Three-month asthma review with repeat spirometryfinishedS
2026-09-14Six-month asthma review after a summer exacerbationfinishedS
2026-08-03Same-day sick visit for wheeze and chest tightness with a coldfinishedS
2026-10-19Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Stop reliever-only albuterol and start budesonide-formoterol maintenance-and-reliever therapy at Step 4 (two inhalations twice daily plus one as needed, up to 12 a day), with a spacer and inhaler-technique teachingcompletedGL-GINA-2025, GL-NAEPP-2020S
Written asthma action plan with symptom and peak-flow zones (green 80 percent or more of personal best, yellow 50 to 79 percent, red below 50 percent), reviewed at every visit and after every exacerbationcompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020S
Pulmonology referral to confirm the diagnosis, assess type 2 inflammation, and advise on exercise-induced symptoms, allergen measures, and treatment stepcompletedGL-GINA-2025, GL-NAEPP-2020S
Asthma Control Test, inhaler technique, adherence, reliever use, triggers, and exacerbation history at every visit; review one to three months after starting controller therapy, then every three to twelve months, and within one week of any exacerbation; spirometry at diagnosis, three to six months after stabilization, then every one to two yearscompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020S
Explain that exercise improves fitness but does not treat airway inflammation; take one reliever inhalation before boxing or rowing; use dust-mite-impermeable bedding covers once sensitization is showncompletedGL-NAEPP-2020, GL-GINA-2025S
Yearly influenza vaccine, pneumococcal vaccination for chronic lung disease, and COVID-19 vaccination by CDC guidancecompletedGL-CMID-2026, GL-ACIP-PNEUMOS

Goals

GoalTargetStatusOutcomeProvenance
Asthma Control Test score of 20 or more by the three-month review2026-06-08completedACT rose from 13 to 22S
FEV1 of 80 percent predicted or more on spirometry after stabilization2026-06-08completedFEV1 89 percent predicted with a normal FEV1/FVC ratioS
No exacerbation needing oral corticosteroids over the six months after starting controller therapy2026-09-14activeNot met: one moderate exacerbation with a cold in August needed a five-day prednisone course; the goal continues for the next six monthsS
Return to full boxing and rowing training without limiting symptoms2026-06-08completedTraining fully by the three-month review, using one reliever inhalation before sessionsS

Functional Status

Mental Status